Herpes Simplex Virus (HSV)-Mediated ICAM-1 Gene Transfer Abrogates Tumorigenicity and Induces Anti-Tumor Immunity

[1]  D. Finkelstein,et al.  Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector , 1998, Gene Therapy.

[2]  A. Jacobs,et al.  Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. , 1997, Human gene therapy.

[3]  J. Schlom,et al.  Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. , 1997, Human gene therapy.

[4]  M. D'Angelica,et al.  Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon. , 1997, The Journal of clinical investigation.

[5]  J. Roth,et al.  Gene therapy for cancer: what have we done and where are we going? , 1997, Journal of the National Cancer Institute.

[6]  M. Brennan,et al.  Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production. , 1996, Human gene therapy.

[7]  M. Iannone,et al.  Xenogeneic ICAM-1 gene transfer suppresses tumorigenicity and generates protective antitumor immunity. , 1996, Gene therapy.

[8]  M. Monden,et al.  Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy. , 1996, British Journal of Cancer.

[9]  D. Blumberg,et al.  Rapid and efficient gene transfer in human hepatocytes by herpes viral vectors , 1995, Hepatology.

[10]  N. Kyprianou,et al.  Enhanced expression of ICAM-1 in a murine fibrosarcoma reduces tumor growth rate. , 1995, The Journal of surgical research.

[11]  P. Anderson,et al.  Dependency on intercellular adhesion molecule recognition and local interleukin-2 provision in generation of an in vivo CD8+ T-cell immune response to murine myeloid leukemia. , 1995, Blood.

[12]  H. Federoff,et al.  Ex vivo hepatic gene transfer in mouse using a defective herpes simplex virus‐1 vector , 1995, Hepatology.

[13]  D. Simmons.  The role of ICAM expression in immunity and disease. , 1995, Cancer surveys.

[14]  P. Lollini,et al.  Immunizing and Curative Potential of Replicating and Nonreplicating Murine Mammary Adenocarcinoma Cells Engineered with Interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, Tumor Necrosis Factor α, Granulocyte-Macrophage Colony-stimulating Factor, and γ-Interferon Gene or Admixed with Conventional Adjuvants , 1994 .

[15]  D. Pardoll,et al.  In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression , 1994, The Journal of experimental medicine.

[16]  S. Koyama.  Immunosuppressive Effect of Shedding Intercellular Adhesion Molecule 1 Antigen on Cell‐mediated Cytotoxicity against Tumor Cells , 1994, Japanese journal of cancer research : Gann.

[17]  P. Lollini,et al.  Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional a , 1994, Cancer research.

[18]  I. Miki,et al.  Simple colorimetric cell-cell adhesion assay using MTT-stained leukemia cells. , 1993, Journal of immunological methods.

[19]  G. Freeman,et al.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Blankenstein,et al.  Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  E. Gilboa,et al.  Regression of bladder tumors in mice treated with interleukin 2 gene- modified tumor cells [published erratum appears in J Exp Med 1993 Jun 1;177(6):following 1831] , 1993, The Journal of experimental medicine.

[23]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[24]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[25]  A. Porgador,et al.  Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. , 1992, Cancer research.

[26]  J. Becker,et al.  Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. , 1991, Journal of immunology.

[27]  D. Pardoll,et al.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.

[28]  C. Stratowa,et al.  Cloning of the human gene for intercellular adhesion molecule 1 and analysis of its 5'-regulatory region. Induction by cytokines and phorbol ester. , 1991, Journal of immunology.

[29]  H. Federoff,et al.  The use of hsv 1 vectors to introduce heterologous genes into neurons implications for gene therapy , 1991 .

[30]  D. S. Webb,et al.  Cytokine-induced enhancement of ICAM-1 expression results in increased vulnerability of tumor cells to monocyte-mediated lysis. , 1991, Journal of immunology.

[31]  P. Kourilsky,et al.  Interleukin 2‐dependent activation of tumor‐specific cytotoxic T lymphocytes in vivo , 1991, European journal of immunology.

[32]  J. Johnson.  The role of ICAM-1 in tumor development. , 1991, Chemical immunology.

[33]  Michael Loran Dustin,et al.  Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. , 1991, Annual review of immunology.

[34]  J. Bryan,et al.  An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[36]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[37]  J. Trowsdale,et al.  Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells , 1989, Nature.

[38]  R. Herberman.  Interleukin-2 therapy of human cancer: potential benefits versus toxicity. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  F. Ognibene,et al.  Cardiorespiratory effects of immunotherapy with interleukin-2. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Michael Loran Dustin,et al.  Supergene families meet in the immune system. , 1988, Immunology today.

[41]  A. Rickinson,et al.  Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein- Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance , 1988, The Journal of experimental medicine.

[42]  T. Springer,et al.  Functional evidence that intercellular adhesion molecule‐1 (icam‐1) is a ligand for lfa‐1d‐ependent adhesion in t cell‐mediated cytotoxicity , 1988, European journal of immunology.

[43]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[44]  A. Chang,et al.  High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. , 1986, JAMA.

[45]  Michael Loran Dustin,et al.  A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. , 1986, Journal of immunology.

[46]  Michael Loran Dustin,et al.  Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). , 1986, Journal of immunology.